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Abstract
Long-term exposure to hypercholesterolemia is the cause of atherosclerosis, which in turn causes cardiovascular and cerebrovascular events. In de-
veloped countries, including Poland, vascular diseases are the main cause of death. They affect an ever younger part of the population, including the 
working population. The authors address the problem of epidemiology of cardiovascular diseases, unsatisfactory detection and treatment, economic 
consequences for the health care system, and the possibilities of using occupational medicine services in the prevention of this health problem. Due to the 
fact that the early detection of diseases caused by high blood cholesterol levels is relatively low in Poland, obligatory occupational medicine examinations 
seem to be a key element of the second-line prevention. Therefore, it seems natural to consider the idea of extending the scope of obligatory examina-
tions and introducing tests that allow lipid disorders to be detected at an early stage. This can contribute to a general improvement of the health of the 
population, and to economic benefits, such as a decrease in the costs of treatment of the disorders that have been detected too late. Broadening the scope 
of occupational examinations is also important from the perspective of public health and epidemiology of cardiovascular diseases, thus being an element 
of prevention of civilization diseases. It means improving health and building health awareness, and it should translate into regular health examinations. 
The performance of these examinations should result not only from the obligation, but also from the patient’s conviction about the importance of early 
detection of disorders, including lipid disorders, for an effective therapy. Int J Occup Med Environ Health. 2019;32(6):865–72
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of changes depend heavily on the length and intensity of 
exposure to risk factors, such as stress, lack of physical ac-
tivity, or poor diet. The phenomenon of a rapidly aging 
society seems important in this context, too.
A high level of cholesterol is the most important modifi-
able risk factor for cardiovascular diseases. Its reduction 
decreases the risk of cardiovascular diseases in the pop-
ulation. Health intervention in the group at the highest 
CVD risk, that is the population group aged 40–59, pro-
duces the best health effects.
Since 1991, a gradual decrease in CVD mortality has been 
observed. However, due to these diseases, the life expec-
tancy of the Polish population is still shorter by 3–7 years, 
compared to the life expectancy in the 15 “old” countries 
of the European Union [2].
There is no doubt that cardiovascular diseases constitute 
the main health risk for the Polish population and a great 
challenge for the Polish health care system. This challenge 
involves the need to use existing organizational and legal 
solutions, such as preventive medical examinations of em-
ployees. These examinations are performed > 4.5 million 
times a year, and each of more than 12.5 million of work-
ers in Poland is obliged to undergo a preventive exami-
nation at least once in 4 years [6], which means that the 
occupational health care system may, and should, be con-
sidered an element of public health aimed at the preven-
tion of civilization disorders, which should result in fitness 
to work being sustained or prolonged.
The risk factors for cardiovascular diseases and their oc-
currence in the Polish population are presented below.
MAIN RISK FACTORS 
FOR CARDIOVASCULAR DISEASES
Cardiovascular diseases are mainly caused by atheroscle-
rosis. The predominant role in etiopathogenesis, develop-
ment and progression of atherosclerosis is played by modi-
fiable risk factors associated with improper lifestyle (poor 
diet, too low physical activity, etc.). These risk factors 
INTRODUCTION
Cardiovascular diseases (CVDs) are the main cause of 
death worldwide. According to the World Health Organ-
isation (WHO), about 17 million people die of CVDs an-
nually (49% of all deaths due to non-communicable dis-
eases). This rate is almost 2 times higher than the mortali-
ty rate for cancer, which is the second cause of death in the 
world. In addition, CVDs are the main cause of premature 
deaths. Data on the European population in 2012 showed 
that CVDs caused 38% and 35% of deaths among women 
and men < 75 years of age, respectively [1].
The epidemiological situation in Poland in 2014 was 
similar: cardiovascular diseases accounted for 45% of all 
deaths (40% among men, 50% among women), thus be-
ing the first cause of death in the Polish population, pre-
ceding cancer. The average was 476 deaths a day, with 
every fifth death being premature. It is worth noting that 
CVDs are becoming the main cause of death in the age 
group > 69 years [2]. In addition, the NATPOL 2011 study 
showed that the incidence of elevated low-density lipopro-
tein cholesterol (LDL-C) was approx. 58% for both sexes. 
Improper levels of total cholesterol (TC) and LDL-C have 
been most frequently found in persons aged 40–59 (> 71% 
of respondents); therefore, this age group is considered to 
be at the highest CVD risk [3].
Data presented in the study of 2016, entitled “Health 
condition of the Polish population and its determinants,” 
show that Poland is one of the developed countries that 
are characterized by a high percentage of premature 
deaths (according to the PYLL index – potential years of 
life lost), where cardiovascular diseases are the first cause 
of death among men (26%), and the second cause of death 
among women (21% preceded by cancer – 41%).
In addition to being the main cause of death, CVDs are 
also the main cause of morbidity, hospitalizations, inva-
lidity and sickness absenteeism [4,5]. It should be empha-
sized that the formation and development of atheroscle-
rotic plaques progress with age, and the pace and type 
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fied for the statin therapy. They receive recommendations 
for a healthy lifestyle (which they often do not follow). The 
initial lack of symptoms can pose a certain health threat, 
since the patient leaves the doctor’s office with a delusive 
feeling of being in full health, and often has no motiva-
tion to follow the recommendations. Consequently, when 
the patient visits the doctor again after many years, he/she 
might already suffer from advanced atherosclerosis, myo-
cardial infarction or stroke. Therefore, the key role of the 
doctor is to make the patient aware of the health threat. 
In this respect, obligatory employee medical examinations 
may prove particularly helpful, as they can help achieve 
a much higher rate of following medical recommendations 
among patients, reaching > 90% [8].
LIPID DISORDERS – GOALS OF TREATMENT
The most important treatment goal is related to LDL-C, 
and it depends on the overall cardiovascular risk. Non-high 
density lipoprotein cholesterol levels can be the secondary 
goal of therapy, especially in patients with high triglycer-
ide levels. There are no treatment goals for triglycerides 
due to the lack of evidence from clinical trials that would 
allow the establishing of such treatment goals. However, 
the level of > 1.7 mmol/l (> 150 mg/dl) is considered to 
be a marker of increased risk. Similarly, although the high 
density lipoprotein cholesterol level is not the treatment 
goal, its concentration < 1.0 mmol/l (< 40 mg/dl) in men 
and < 1.2 mmol/l (< 45 mg/dl) in women can be consid-
ered a marker of increased risk.
TREATMENT
It is generally recognized that, regardless of the interven-
tion, a reduction in the LDL-C level by 1 mmol/l results in 
a decreased risk of major cardiovascular events by 22%, 
deaths from the ischemic heart disease by 20%, deaths 
from vascular causes by 14%, and deaths from all causes 
mentioned by 10% [9]. It is worth noting that a drop in 
LDL-C to very low values (e.g., 0.8 mmol/l or about 
may lead to lipid metabolism disorders (hyperlipidemia) 
or hypertension, which are considered to be the main 
risk factors for CVDs. A multicenter INTERHEART 
study, the results of which were included in the WOBASZ 
(Wieloośrodkowe Ogólnopolskie Badanie Stanu Zdrowia 
Ludności) study [4], showed that the 2 risk factors men-
tioned above, nicotine addiction, diabetes, abdominal obe-
sity and psychosocial factors, as well as cardioprotective 
factors: fruit and vegetable intake, low alcohol consump-
tion and regular physical activity, influenced 90% and 94% 
of cardiovascular events in men and women, respectively. 
It is worth noting that this relationship was demonstrated 
in all regions of the world and in all age groups.
A reduction of the risk factors, as the best method of decreas-
ing CVD mortality, has been confirmed in numerous studies 
around the world, which were presented in the introduction 
to the WOBASZ analysis. Similar results were obtained in 
an analysis conducted in Poland in 1991–2005, which showed 
that a reduction of the risk factors in the population of adult 
Poles brought about a 54% decrease in mortality from coro-
nary diseases, whereas improved access to cardiac and car-
diac surgery treatment methods resulted in a 37% reduction 
in the said mortality. To quote the NATPOL research: “the 
intensity of CVD factors is one of the most important deter-
minants of life expectancy in Poland” [7].
In order to implement a proper health intervention, it is nec-
essary to know the parameters related to cholesterol con-
centration in the blood. Currently, detection of cholesterol-
related risks rests mainly with primary care physicians who 
are usually approached by the patient too late, which sig-
nificantly delays the cardiologist’s intervention. As this situa-
tion significantly limits doctors’ options, it appears necessary 
to develop and implement systemic solutions in this area. 
A person with a significantly increased blood cholesterol 
level is usually qualified for the statin therapy. However, 
a problem of not following doctor’s instructions can arise.
Another problematic issue is related to persons with 
slightly increased cholesterol levels, who are not yet quali-
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pertension, tobacco addiction syndrome, diabetes, over-
weight, negative family history), in all men > 40 years of 
age and women > 50 years of age, as well as in patients 
with cardiovascular diseases, chronic kidney diseases or 
autoimmune diseases. In the case of a proper lipid profile, 
it is advisable to repeat the test at least every 3–5 years. 
Having achieved the target LDL-C level, patients with 
hypercholesterolemia should repeat the test once a year. 
It should be emphasized that, in most cases, it is a mistake 
not to determine the LDL-C level but to measure the total 
cholesterol level only [15].
Most cases of hypercholesterolemia in Poland remain un-
diagnosed: WOBASZ II research shows that up to 61% of 
persons with hypercholesterolemia are not aware of the 
disease. This explains the low percentage of hypercho-
lesterolemia control and the fact that only 6% of persons 
with hypercholesterolemia are successfully treated.
RELATIONSHIP BETWEEN DYSLIPIDEMIA 
AND ECONOMIC FACTORS
The total cost of prevention depends on many factors, in-
cluding whether it is calculated for a healthy or ill person, 
a person at risk or not, the type of intervention applied 
for a particular person, the country of analysis, and the 
reimbursement for a given medical procedure. The use of 
generic drugs can significantly affect cost efficiency [16], 
whereas the costs of laboratory tests in different regions 
of the same country can significantly change the total costs 
of prevention. The WHO is of the opinion that political 
and environmental changes could result in a reduction 
of the costs of cardiovascular diseases in all countries to 
< 1 USD/person/year [17]. In addition, data from the 
United Kingdom show that decreasing the cardiovascular 
risk by 1% could prevent 25 000 cases of cardiovascular 
diseases, and bring financial benefits in the amount of 
40 million EUR/year [18].
Analyzes of KPMG showed that the total cost of CVD di-
agnosis and treatment in 2011 amounted to PLN 15.3 bil-
30 mg/dl) improves the patient’s prognosis to a slightly 
lesser extent than interventions in patients with higher 
cholesterol levels [10].
EVERYDAY PRACTICE
Recent studies have shown that although hypercholesterol-
emia control in the Polish population is gradually improving, 
it is still not satisfactory. Currently, hypercholesterolemia is 
effectively controlled only in 6% of patients (i.e., cholesterol 
concentration is reduced to the recommended level) [11]. 
The reason behind this alarming situation is a very high 
percentage of unrecognized hypercholesterolemia cases, 
amounting to 61%. Furthermore, 17% of the patients diag-
nosed with hypercholesterolemia are not treated. Low hy-
percholesterolemia control is one of the main reasons for 
the high incidence of, and mortality from, cardiovascular 
diseases in Poland, which cause 45.7% of all deaths [12].
Hypercholesterolemia is not always optimally controlled in 
the patients after myocardial infarction [13]. Basic preven-
tion goals are often not achieved. One study revealed that, 
on average, 1 year after hospitalization for acute coronary 
syndrome or myocardial re-vascularity, only 28.1% of pa-
tients were controlled for hypercholesterolemia (LDL-C 
< 1.8 mmol/l), whereas in 71.9%, 38,6%, 24.4% and 10.3% 
of patients cholesterol levels amounted to ≥ 1.8 mmol/l, 
≥ 2.5 mmol/l, ≥ 3.0 mmol/l and ≥ 4.0 mmol/l, respective-
ly [14]. The study showed that the patients’ age and the fac-
tors related to the organization of the health care system 
affected the frequency of statin use, while demographic 
and clinical factors determined the hypercholesterolemia 
control after hospitalization for the ischemic heart disease. 
Insufficient hypercholesterolemia control in persons from 
the highest risk group is one of the causes of high mortality 
in this group.
SCREENING AND CONTROL TESTS
Screening tests should be performed in persons with at 
least 1 risk factor for cardiovascular diseases (e.g., hy-
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by 25–55% with the use of various means of therapy [20]. 
Systematic preventive examinations can help detect the 
disease in its initial phase, as well as prevent the disease 
progression and its negative consequences. They can not 
only influence the health of the population, but also bring 
measurable economic benefits.
In the light of the above, besides the identification and 
treatment of persons at a high cardiovascular risk, it is of 
much importance to detect lipid disorders in their early 
phase, and to provide professional medical counseling. 
According to the European Society of Cardiology (ESC) 
and the European Atherosclerosis Society (EAS) guide-
lines of 2016, effective protective interventions in the early 
stage of the disease, which are performed in the group of 
persons at a moderate risk, can prevent a further increase 
in the total cardiovascular risk, raise the awareness of the 
threats related to the increased cardiovascular risk, im-
prove the flow of information on the CVD risk, and pro-
mote primary prevention activities [21].
PREVENTIVE MEDICAL EXAMINATIONS 
OF EMPLOYEES
The negative situation in the field of the diagnosis and con-
trol of hypercholesterolemia in Poland could be improved 
through the implementation of lipid profile tests, as part 
of pre-employment and routine preventive medical exami-
nations of employees. Preventive examinations are per-
formed in accordance with the Regulation of the Minister 
of Health and Social Care of 30 May 1996 [22]. Determina-
tion of the cholesterol level is obligatory if a job position is 
related to adverse psychosocial factors (risks resulting from 
a constant influx of information and readiness to respond, 
making decisions, responsibility, and life-threatening haz-
ards) and occupational toxic agents (carbon disulfide). 
However, this solution has certain limitations:
 – determination of the cholesterol level is obligatory 
during the pre-employment and routine examinations, 
only for those workers who have received from their 
lion, including hospitalization costs of PLN 7.5 billion, the 
costs of outpatient care of PLN 3.7 billion, and the costs 
of pharmaceutical drugs of PLN 4.1 billion. Indirect costs 
were much higher, amounting to PLN 26.6 billion annu-
ally, of which PLN 16.6 billion were allocated to early pen-
sions and retirement pensions, PLN 8 billion were losses 
resulting from premature mortality, and PLN 2 billion 
were the costs of sick leaves [19].
In 2013, expenditure on benefits related to the incapacity 
for work was at the level of PLN 32 276.1 million, which 
was 6% more than in 2012. Expenses on the incapacity 
for work pensions constituted the highest percentage and 
amounted to 48.5%, whereas expenses related to absen-
teeism from work amounted to 41.3%. Other expenses 
covered the costs of social pensions (5.9%), the costs of 
rehabilitation benefits (3.8%), and the costs of medical re-
habilitation in the framework of pension prevention of the 
Social Insurance Institution (0.5%).
Cardiovascular diseases (ICD-10: I00–I99) generated the 
second highest costs in 2013, accounting for 14.5% of all 
costs, and they were preceded only by mental and behav-
ior disorders (ICD-10: F00–F99), which generated 16.8% 
of costs. Considering patients’ sex and incapacity for work, 
the highest costs were generated by men with cardiovas-
cular diseases (20.5%). When calculating expenditure on 
the incapacity for work in 2013, the expenditure ratio per 
person covered by health insurance was measured, and it 
amounted to PLN 198.38 for cardiovascular diseases.
Although studies conducted on the basis of evidence-
based medicine are not reliable enough, it can be assumed 
that expenses on preventive activities are much lower than 
the costs of complex diagnostic procedures and treatment, 
of both conservative and invasive nature. It should be em-
phasized that the prophylaxis of cardiovascular diseases 
can produce much better results than therapy, while in-
curring much lower costs. Mortality due to cardiovascular 
diseases can be reduced by 45–75% with the use of pre-
ventive measures reducing the intensity of risk factors, and 
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developed on the basis of the results of tests carried out 
by a physician providing preventive care to the patient, 
and be individually adapted to the needs of the employee. 
There is a difference between the needs of a population 
in a production plant with the majority of workers aged 
> 50 suffering from cardiovascular diseases or being at 
risk of these diseases, and a group of young employees 
of a bank, burdened primarily with psychosocial factors. 
Health activities should be based on the results of scien-
tific research and be preceded by certain arrangements be-
tween the occupational physician and the employer. The 
effects of such activities require constant monitoring and 
appropriate interventions. Changes in the labor market, 
the development of technology, including digitization, the 
prevalence of psychosocial burden, and an increase in the 
frequency of civilization diseases require the development 
of integrated models supporting health and productivity. 
Such initiatives call for financial support from the em-
ployer and a good cooperation with occupational health 
services. Public participation may be an alternative to the 
above solutions; thus, it seems that occupational health 
services should be included in performing the prophylac-
tic programs financed by the National Health Fund or the 
Ministry of Health, as well as regional EU programs or 
incapacity pension prevention measures funded by the So-
cial Insurance Institution.
Advantage should be taken of the obligatory character of 
health check-ups of all employees, which gives full partici-
pation in the enrolment into a prophylactic program. So, 
the possible step-by-step procedure is as follows:
 – during an obligatory employee’s examination financed 
by the employer, a lipid profile blood test, funded by 
public institutions, is additionally performed;
 – based on laboratory results and medical examinations, 
the patient is given full information and further advice 
on modifications in his/her lifestyle, diet, etc., and/or on 
the necessity to continue diagnostics/treatment in a pri-
mary health care unit;
employer a referral with the indication of the above 
mentioned adverse occupational factors, which are 
listed in the regulation mentioned above;
 – according to the current practice of determining the 
occupational risk, which at the same time implies the 
scope of additional examinations (including cholesterol 
level determination), adverse psychosocial factors are 
mainly associated with decision-making job positions. 
However, changes in the nature of work and current ex-
pectations towards an increasing number of employees 
are related to the exposure to professional stress result-
ing from time pressure and requirements that are often 
not adjusted to physical or intellectual capabilities of an 
employee. Therefore, it can be assumed that the num-
ber of persons undergoing obligatory cholesterol tests 
is lower than it is needed;
 – it is a standard and common procedure to determine 
only the total level of cholesterol, whereas performing 
the full lipid profile requires the approval of the em-
ployer who finances the medical examination.
It seems that extensive preventive medical examinations 
in the framework of preventive activities of occupational 
medicine should become an effective element of early 
detection and treatment of dyslipidemia. In Poland, only 
some employers decide to finance additional pro-health 
activities. Prophylactic programs aimed at dyslipidemia 
and cardiovascular diseases comprise 3 areas:
1. Controlling risk factors by health promotion programs 
oriented towards healthy diet, physical activity, body 
mass control, and smoke-free environment.
2. Providing additional health care plans and pack-
ages covering laboratory tests and access to medical 
specialists.
3. Financing additional screening tests performed during oc-
cupational health check-ups, e.g., the lipid profile or glu-
cose level, not included in the obligatory scope of tests.
These activities lack cooperation with occupational health 
care. However, an integrated health program should be 
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 – the lipid profile is evaluated regularly (every 3–5 years 
or as required), but not at every health check-up, which 
may be monitored with the use of an IT system.
SUMMARY
The most common factor for the occurrence of cardio-
vascular diseases is dyslipidemia. Lipid disorders, which 
can lead to the development of atherosclerosis, affect 
18 million Poles. Vascular complications, which are 
a natural consequence of a long-term exposure to hy-
percholesterolemia, are becoming a problem not only 
for the patient but also for the health care system. The 
costs of treatment of cardiovascular diseases are very 
high. Therefore, it seems justified to conduct extensive 
educational campaigns for early diagnosis of lipid dis-
orders, and other social activities in the field of primary 
prevention, which can be of fundamental importance for 
the reduction of mortality from cardiovascular diseases. 
Systematic preventive health examinations from an early 
age could contribute to the detection of diseases at an 
early stage, and thus reduce morbidity and mortality re-
lated to the occurrence of cardiovascular diseases, and 
lower the costs of treatment and rehabilitation of pa-
tients. The implementation of consistent activities in the 
field of first-, second- and third-line prevention, as part 
of preventive care for workers, should be an additional 
element in the early detection and treatment of dyslip-
idemia. The effectiveness of these activities will depend 
both on the involvement of the occupational health care 
system and employers’ readiness to finance additional 
pro-health activities for their workers, as well as on pub-
lic institutions’ support.
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